Breanna A Nguyen1, Jonhan Ho2, Jacinto S De La Cruz Diaz1, Stephen Nishimura3, Daniel H Kaplan4. 1. Department of Immunology, University of Pittsburgh, Pittsburgh, PA, United States; Department of Dermatology, University of Pittsburgh, Pittsburgh, PA, United States. 2. Department of Dermatology, University of Pittsburgh, Pittsburgh, PA, United States. 3. Department of Pathology, University of California San Francisco, San Francisco, CA, United States. 4. Department of Immunology, University of Pittsburgh, Pittsburgh, PA, United States; Department of Dermatology, University of Pittsburgh, Pittsburgh, PA, United States. Electronic address: dankaplan@pitt.edu.
Abstract
BACKGROUND: Integrins avβ6 and avβ8 are expressed by keratinocytes and transactivate latent TGFβ. In a murine model, integrin mediated activation of TGFβ has been shown to be critical in maintaining skin homeostasis, specifically playing roles in epidermal retention of Langerhans cells and resident memory cells T cells (Trm). OBJECTIVE: We examine expression of Integrins β6 and β8 in human skin, inflammatory skin disease, benign nevi, and melanoma and hypothesize that integrin expression is dysregulated in disease. METHODS: Using immunohistochemistry, we stained tissue from normal human skin (n = 8), psoriasis (n = 6), atopic dermatitis (n = 6), lichen planus (n = 5), benign nevi (n = 24), and melanoma (n = 25) with anti-integrin β6 and anti-integrin β8 to survey expression pattern. We also performed a retrospective chart review in the melanoma cohort to examine if integrin β6 and β8 expression was associated with increased Breslow depth and worse prognostic staging. RESULTS: Here, we show that human keratinocytes express integrins β6 and β8, similar to murine keratinocytes. We also found that inflammatory skin conditions have increased Integrin β6, but not Integrin β8 expression. Furthermore, we identified that melanomas have greatly increased expression of integrin β8 compared to nevi. Additionally, high expression of integrin β8 was correlated with greater Breslow depth at diagnosis and with worse prognostic staging. CONCLUSION: These findings demonstrate that like murine keratinocytes, human keratinocytes express integrin β6 and β8 under steady state conditions. Moreover, altered integrin expression may participate in the development or maintenance of cutaneous inflammation as well as tumor immune evasion.
BACKGROUND: Integrins avβ6 and avβ8 are expressed by keratinocytes and transactivate latent TGFβ. In a murine model, integrin mediated activation of TGFβ has been shown to be critical in maintaining skin homeostasis, specifically playing roles in epidermal retention of Langerhans cells and resident memory cells T cells (Trm). OBJECTIVE: We examine expression of Integrins β6 and β8 in human skin, inflammatory skin disease, benign nevi, and melanoma and hypothesize that integrin expression is dysregulated in disease. METHODS: Using immunohistochemistry, we stained tissue from normal human skin (n = 8), psoriasis (n = 6), atopic dermatitis (n = 6), lichen planus (n = 5), benign nevi (n = 24), and melanoma (n = 25) with anti-integrin β6 and anti-integrin β8 to survey expression pattern. We also performed a retrospective chart review in the melanoma cohort to examine if integrin β6 and β8 expression was associated with increased Breslow depth and worse prognostic staging. RESULTS: Here, we show that human keratinocytes express integrins β6 and β8, similar to murine keratinocytes. We also found that inflammatory skin conditions have increased Integrin β6, but not Integrin β8 expression. Furthermore, we identified that melanomas have greatly increased expression of integrin β8 compared to nevi. Additionally, high expression of integrin β8 was correlated with greater Breslow depth at diagnosis and with worse prognostic staging. CONCLUSION: These findings demonstrate that like murine keratinocytes, human keratinocytes express integrin β6 and β8 under steady state conditions. Moreover, altered integrin expression may participate in the development or maintenance of cutaneous inflammation as well as tumor immune evasion.
Authors: Jonathan L Hecht; Brian M Dolinski; Humphrey A Gardner; Shelia M Violette; Paul H Weinreb Journal: Appl Immunohistochem Mol Morphol Date: 2008-12
Authors: Poshala Aluwihare; Zhenyu Mu; Zhicheng Zhao; Dawen Yu; Paul H Weinreb; Gerald S Horan; Shelia M Violette; John S Munger Journal: J Cell Sci Date: 2009-01-15 Impact factor: 5.285
Authors: Alexander Vogetseder; Svenja Thies; Barbara Ingold; Patrick Roth; Michael Weller; Peter Schraml; Simon L Goodman; Holger Moch Journal: Int J Cancer Date: 2013-06-10 Impact factor: 7.396
Authors: Jeffrey E Gershenwald; Richard A Scolyer; Kenneth R Hess; Vernon K Sondak; Georgina V Long; Merrick I Ross; Alexander J Lazar; Mark B Faries; John M Kirkwood; Grant A McArthur; Lauren E Haydu; Alexander M M Eggermont; Keith T Flaherty; Charles M Balch; John F Thompson Journal: CA Cancer J Clin Date: 2017-10-13 Impact factor: 508.702